Conference on Retroviruses and Opportunistic Infections (CROI 2018)
4 March 2018. Related: News.
4–7 March 2018, Boston
Introduction
Simon Collins, HIV i-Base
This year the annual Conference on Retroviruses and Opportunistic Infections (CROI) being held in Boston was preceded by a storm along the west coast that disrupted travel for many participants, and resulted in cancelling some earlier workshops.
This included the important annual community cure workshop, that provides a chance to review the most important research expected at CROI.
Cure-related research will be a main theme this year, with many presentations on approaches to define and shift the reservoir of latently infected CD4 cells, including important proof-of-principle results in animal studies (see below).
And while CROI will include studies on nearly every aspect of HIV, other major themes include new and better treatments (including global access), HIV prevention (including PrEP) and important studies on managing coinfections and complications (including TB).
The full programme is now available online and abstracts and webcasts from oral presentations will become available immediately after the presentations. Approximately 1100 new studies were selected for the conference this year.
Early reports from CROI 2018 will be posted as links below as they become available.
- Inching towards an HIV cure: bNAb and TLR-7 agonist reduce viral rebound off-ART in macaques
- No HIV evolution in plasma or lymph nodes on suppressive ART and no impact from further intensification
- Dual therapy can reduce TB prophylaxis from nine months to one: fewer side effects and more people complete treatment
- Twice-daily dolutegravir is effective and tolerable with rifampicin
- Once-daily tenofovir alafenamide appears sufficient when dosed with rifampicin
- Efavirenz 400 mg can be given with anti-tuberculosis treatment
- Bictegravir at CROI 2018: switching studies and drug resistance analyses
- PrEP at CROI 2018 (part 1): Access in Australia and the US
- PrEP at CROI 2018 (part 2): Animal studies for future drugs
- BHIVA best of CROI feedback workshops